<DOC>
	<DOCNO>NCT02348216</DOCNO>
	<brief_summary>This single arm , open-label , multi-center , phase 1/2 study , determine safety efficacy KTE-C19 , autologous anti-CD19 chimeric antigen receptor ( CAR ) -positive T cell therapy , refractory aggressive Non-Hodgkin Lymphoma ( NHL ) .</brief_summary>
	<brief_title>A Phase 1-2 Multi-Center Study Evaluating KTE-C19 Subjects With Refractory Aggressive Non-Hodgkin Lymphoma ( ZUMA-1 )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>Key Inclusion Criteria 1 . Histologically confirm : Diffuse Large B Cell Lymphoma ( DLBCL ) Primary Mediastinal Large B Cell Lymphoma ( PMBCL ) Transformation Follicular Lymphoma ( TFL ) 2 . Chemotherapyrefractory disease , define one following : No response last line therapy i. PD best response recent therapy regimen ii . SD best response recent therapy duration longer 6 month last dose therapy OR Refractory postASCT . Disease progression relapse less equal 12 month ASCT ( must biopsy proven recurrence relapse subject ) ii . If salvage therapy give postASCT , subject must response relapse last line therapy 3 . Subjects must receive adequate prior therapy include minimum : antiCD20 monoclonal antibody unless investigator determines tumor CD20negative anthracycline contain chemotherapy regimen subject transform FL must receive prior chemotherapy follicular lymphoma subsequently chemorefractory disease transformation DLBCL 4 . At least one measurable lesion per revise IWG Response Criteria 5 . Age 18 old 6 . Eastern cooperative oncology group ( ECOG ) performance status 0 1 7 . ANC ≥ 1000/uL 8 . ALC &gt; 100/uL 9 . Platelet count ≥ 75,000/uL 10 . Adequate renal , hepatic , pulmonary cardiac function define : Creatinine clearance ( estimate Cockcroft Gault ) &gt; 60 mL/min Serum ALT/AST &lt; 2.5 ULN Total bilirubin &lt; 1.5 mg/dl , except subject Gilbert 's syndrome Cardiac ejection fraction &gt; 50 % , evidence pericardial effusion determine ECHO , clinically significant pleural effusion Baseline oxygen saturation &gt; 92 % room air 11 . All subject legally appoint representatives/caregivers , must personally sign date IRB/IEC approve consent form initiating study specific procedure activity . Key Exclusion Criteria 1 . History malignancy nonmelanoma skin cancer carcinoma situ ( e.g . cervix , bladder , breast ) follicular lymphoma unless disease free least 3 year 2 . History allogeneic stem cell transplantation 3 . Prior CAR therapy genetically modify T cell therapy 4 . Presence fungal , bacterial , viral , infection uncontrolled require IV antimicrobial management . Simple UTI uncomplicated bacterial pharyngitis permit respond active treatment 5 . Known history infection HIV hepatitis B ( HBsAG positive ) hepatitis C virus ( antiHCV positive ) . A history hepatitis B hepatitis C permit viral load undetectable per quantitative PCR and/or nucleic acid test 6 . Subjects detectable cerebrospinal fluid malignant cell , brain metastasis , history CNS lymphoma , cerebrospinal fluid malignant cell brain metastases 7 . History presence CNS disorder seizure disorder , cerebrovascular ischemia/hemorrhage , dementia , cerebellar disease , autoimmune disease CNS involvement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>